Anti-CD79b (SN8)-MCC-DM1 ADC

  • 1.00 Dollar US$
  • Published date: November 22, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CD79B monoclonal antibody (SN8) conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

Result 0 votes
Jerry Carter
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Fraud & Abuse, Stark & Anti-Kickback Issues

    Fraud & Abuse, Stark & Anti-Kickback Issues

    Drug Development Fremont (California) December 4, 2019 139.00 Dollar US$

    Overview: The presentation will provide an overview of the Federal Stark and Anti-Kickback laws and corresponding regulations including the history and purpose of these laws. The presenter will provide the background upon which these laws were determ...

  • E. coli Galactosidase alpha [His]

    E. coli Galactosidase alpha [His]

    Drug Development Shirley (New York) October 25, 2019 10.00 Dollar US$

    Alpha-galactosidase is a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It is encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha...

  • COMPUTER MODELING SERVICES FOR DRUG DISCOVERY

    COMPUTER MODELING SERVICES FOR DRUG DISCOVERY

    Drug Development Kyiv (Kyiv reg) October 7, 2019 Check with publisher

    Otava Research Institute is pleased to share with new launched services and products for your drug discovery research projects. End-To-End Computer Aided Drug Discovery Services Using our 250,000+ compounds collection and proprietary software we can ...